Newron Pharmaceuticals S.p.A. Stock Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
10:05:42 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 13.30 EUR | +3.50% |
|
-0.37% | -50.09% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 274M 318M 257M 235M 442M 30.42B 444M 3.05B 1.19B 15.36B 1.2B 1.17B 50.92B | P/E 2026 * |
-9.71x | P/E 2027 * | 35.6x |
|---|---|---|---|---|---|
| Enterprise Value | 313M 363M 293M 268M 505M 34.71B 506M 3.48B 1.36B 17.52B 1.36B 1.33B 58.1B | EV / Sales 2026 * |
28.9x | EV / Sales 2027 * | 6.45x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Newron Pharmaceuticals S.p.A.
| 1 day | +3.50% | ||
| 1 week | -0.37% | ||
| Current month | +5.56% | ||
| 1 month | +4.72% | ||
| 3 months | -13.07% | ||
| 6 months | -35.90% | ||
| Current year | -50.09% |
| 1 week | 12.85 |  | 13.3 |
| 1 month | 12.4 | | 14.1 |
| Current year | 12.05 | | 33.55 |
| 1 year | 8.55 | | 33.55 |
| 3 years | 4.2 | | 33.55 |
| 5 years | 1 | | 33.55 |
| 10 years | 1 | | 33.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.50% | -0.37% | - | - | 318M | |
| -0.78% | -1.42% | +2.96% | +21.65% | 50.47B | |
| -6.00% | -0.75% | +447.48% | +535.14% | 44.56B | |
| -0.24% | +0.74% | +37.18% | +16.26% | 43.08B | |
| -1.55% | -2.07% | +19.83% | +71.70% | 41.7B | |
| -0.31% | -0.83% | +19.47% | +48.24% | 33.21B | |
| -1.79% | -3.24% | +26.32% | +125.06% | 16.77B | |
| -0.58% | -2.12% | - | - | 16.28B | |
| -0.88% | -0.66% | +11.63% | +27.62% | 14.58B | |
| -1.66% | -1.25% | +78.49% | +42.97% | 13.92B | |
| Average | -1.03% | -1.06% | +80.42% | +111.08% | 30.51B | |
| Weighted average by Cap. | -1.70% | -1.06% | +96.28% | +129.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.58M 10.17M 9.28M 17.48M 1.2B 17.54M 121M 47.06M 607M 47.24M 46.22M 2.01B | 44.83M 52.03M 42.03M 38.37M 72.28M 4.97B 72.51M 499M 195M 2.51B 195M 191M 8.32B |
| Net income | -31.17M -36.18M -29.23M -26.68M -50.27M -3.46B -50.43M -347M -135M -1.75B -136M -133M -5.79B | 5.02M 5.83M 4.71M 4.3M 8.1M 557M 8.13M 55.88M 21.8M 281M 21.89M 21.41M 933M |
| Net Debt | 38.68M 44.89M 36.27M 33.11M 62.37M 4.29B 62.57M 430M 168M 2.17B 169M 165M 7.18B | 14.72M 17.08M 13.8M 12.6M 23.73M 1.63B 23.8M 164M 63.87M 824M 64.12M 62.73M 2.73B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | €13.30 | +3.50% | 0 |
| 27/08/26 | €12.85 | -1.15% | 0 |
| 26/08/26 | €13.00 | +0.78% | 0 |
| 25/08/26 | €12.90 | -2.64% | 0 |
| 24/08/26 | €13.25 | -0.75% | 500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
Select your edition
All financial news and data tailored to specific country editions
